122 results about "Oxidative phosphorylation" patented technology

The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.

The present invention belongs to the field of insecticides, and relates to a pest-killing and mite-killing composition, which contains an active component A and an active component B, a weight part ratio of the component A to the component B is 1:99-99:1, the active component A is selected from a compound I represented by the following structural formula, the active component B is selected from an organic phosphorus pest/mite killing agent, a nicotine type acetylcholine receptor (nAChR) agonist pest/mite killing agent, an apastia pest/mite killing agent, a proton gradient interference and oxidative phosphorylation affecting uncoupling pest/mite killing agent, a nereistoxin analog pest/mite killing agent, a Ryania receptor regulating pest/mite killing agent, a voltage-dependent sodium ion channel blocking pest/mite killing agent, an ecdysone receptor stimulating pest/mite killing agent, an amino butyric acid (GABA) gated chloride channel antagonism pest/mite killing agent, a microorganism pest/mite killing agent or other pest/mite killing agents, and the active component A has the following structure. The composition of the present invention has advantages of significant synergy, resistance delaying and the like, and can be used for prevention and control of a variety of pests. The compound I is defined in the instruction.

This disclosure relates to a pharmaceutical composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that is a serotonin metabolite.

The present invention relates to a culture medium suitable for mammalian cell, tissue or embryo growth in vitro in which enhancers of oxidative phosphorylation are included. These enhancers include coenzyme Q, alpha.lipoic acid, acetyl-L-carnitine, alpha.tocopherol, These products are introduced into the medium in a soluble form through the use of either a polysorbate surfactant such as Tween ™ or a preparation containing lecithin and surfactant.

The invention discloses a multi-parameter water quality analyzer. The multi-parameter water quality analyzer comprises a hand-held controller and at least one intelligent sensor, wherein the hand-held controller comprises a battery, a battery management module, a display module, a first DC/DC (Direct Current) module, a second DC/DC module, a first central processing unit, a keyboard and a first analogue-to-digital interface; each intelligent sensor comprises a second central processing unit, a third DC/DC module, a second analogue-to-digital interface, a reference voltage source, a signal acquisition module and a sensor. The multi-parameter water quality analyzer is provided with a plurality of sensors, thus being capable of detecting parameters such as PH (potential of hydrogen), OPR (Oxidative Phosphorylation), electrical conductivity and dissolved oxygen content in water, comprehensively detecting the water quality and accurately judging the water quality; meanwhile, the detection part is separated from the observation part so that a user can observe the detected water quality parameters by use of the hand-held controller in the finite range without being restricted to a water quality detection site; the multi-parameter water quality analyzer is provided with the rechargeable battery, thus being capable of working normally without external power source; therefore, the analyzer can be applied to remote water quality detection sites conveniently.

The use of compositions which include one or more inhibitors of the citric acid, TCA, cycle and/or one or more inhibitors of oxidative phosphorylation for the treatment of cellular proliferation is disclosed. The composition is administered to or in the region of the proliferating cells or in a resection scar or cavity.

A mitochondria targeted gold nanoparticle (T-3-BP-AuNP) decorated with 3-bromopyruvate (3-BP) and delocalized lipophilic triphenylphosphonium (TPP) cations to target the mitochondrial membrane potential (Δψm) was developed for delivery of 3-BP to cancer cell mitochondria by taking advantage of higher Δψm in cancer cell compared to normal cells. This construct showed remarkable anticancer activity in prostate cancer cells compared to non-targeted construct NT-3-BP-AuNP and free 3-BP. Anticancer activity of T-3-BP-AuNP was further enhanced upon laser irradiation by exciting the surface plasmon resonance band of AuNP and thereby utilizing a combination of 3-BP chemotherapeutic and AuNP photothermal effects. T-3-BP-AuNPs showed markedly enhanced ability to alter cancer cell metabolism by inhibiting glycolysis and demolishing mitochondrial oxidative phosphorylation in prostate cancer cells. Our findings demonstrated that mitochondria targeted and concerted chemo-photothermal treatment of glycolytic cancer cells with a single NP may have promise as a new anticancer therapy.

A system and methods for calculating at least one unknown metabolic flux of a plurality of cells. In one embodiment, the method includes the steps of constructing a metabolic network having a plurality of reaction components, the reaction components representing at least glycolysis, reduction of pyruvate to lactate, TCA cycle, and oxidative phosphorylation, measuring at least two metabolic rates of a plurality of cells corresponding to at least two of the metabolic network reactions, and calculating metabolic fluxes of a plurality of cells for the rest of the metabolic network reactions from at least two measured metabolic rates of a plurality of cells corresponding to at least two of the reactions.

The invention discloses a diluent for in-vitro low temperature preservation of boar semen and a preparation method thereof. The diluent comprises following components: broad-spectrum antibiotic bacteriostatic agents of D-fructose, 2-amino-2-hydroxymethyl-1,3-propanediol, trisodium citrate, sodium bicarbonate, citric acid, disodium ethylene diamine tetraacetate, N-acetyl-cysteine, skim milk powder, yolk freeze-dried powder, amikacini sulfatis and the like. The diluent for the in-vitro low temperature preservation of the boar semen is suitable for preserving the fresh boar semen at low temperature (4-5 DEG C). The diluent significantly inhibits injury caused to sperm structure during the low temperature preservation process, maintains glucose metabolism and oxidative phosphorylation metabolism processes of boar sperm, effectively prolongs survival time of the boar sperm in the low temperature preservation, and significantly improves use efficiency of the high quality breeding boar semen and economic benefit of breeding.

The invention relates to an application of an energy metabolism-interfering drug in recurrence of pancreatic cancer. Specifically, the invention discloses a pharmaceutical composition which comprisescarboxyamidotriazole or a pharmaceutically acceptable salt thereof and a glycolytic inhibitor. Carboxyamidotriazole and the glycolysis inhibitor are used for blocking from oxidative phosphorylation and glycolysis ways respectively, so the content of ATP in cells can be significantly reduced, the vitality and self renewal of pancreatic cancer stem cells are seriously destroyed, and thus the recurrence of pancreatic cancer after drug treatment can be delayed.

The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.

The invention discloses a nano-drug of a hybrid membrane loaded oxidative phosphorylation inhibitor and a preparation method of the nano-drug, and relates to the technical field of drug carriers. The nano-drug comprises an inner core and a shell; the outer shell covers the periphery of the inner core; the inner core comprises ROS-responsive drug-loaded nano-particles; drugs loaded by the ROS-responsive drug-loaded nano-particles are oxidative phosphorylation inhibitors; and the shell is a mixed membrane of a mitochondrial membrane and a tumor cell membrane. The nano-drug can cross BBB and reach a tumor site by virtue of homologous targeting of the tumor cell membrane, and can perform homologous target and can enter mitochondria by virtue of the mitochondrial membrane, the ROS-responsive drug-loading nano-particle is in a high-level ROS environment of the mitochondria, the core swells and degrades to release the loaded substance oxidation phosphorylation inhibitor, therefore, safe and efficient targeted drug therapy is realized. Through wrapping of the shell, the defect that the half-life period of the loaded medicine in the blood is short is avoided, and long circulation of the medicine in the blood is protected to a great extent.

A composition for supporting endogenous systems related to life span, inhibiting mTOR, and reducing damage associated with oxidative phosphorylation. The composition comprises an upregulating compound mixture configured to upregulate an endogenous antioxidant system, an exogenous antioxidant mixture configured to inhibit oxidation of biomolecules by reactive oxygen species, and a mineral mixture configured to provide one or more cofactors to a endogenous antioxidant enzyme. The endogenous antioxidant system includes regulation of mitophagy through mTOR mediated regulation, and a Nrf2 transcription factors that promotes transcription of antioxidant genes.